Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease

Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer’s Disease

(2012) Jeffrey Cummings et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Could cholinesterase inhibitors be harmful over the long term?

(2011) Lon S. Schneider   INTERNATIONAL PSYCHOGERIATRICS

Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing

(2011) Alessandro Sona et al.   INTERNATIONAL PSYCHOGERIATRICS

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

(2011) Jos Prickaerts et al.   NEUROPHARMACOLOGY

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease

(2010) L. Parnetti et al.   ACTA NEUROLOGICA SCANDINAVICA

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

(2010) John Q. Trojanowski et al.   Alzheimers & Dementia

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

Safety and Tolerability of Donepezil at Doses up to 20 mg/day

(2009) Rachelle S Doody et al.   DRUGS & AGING

Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial

(2009) R. S. Doody et al.   NEUROLOGY

Safety and efficacy of galantamine in subjects with mild cognitive impairment

(2008) B. Winblad et al.   NEUROLOGY